Veeva Systems (VEEV) AI Stock Analysis

Compare

4,580 Followers

Top Page

Veeva Systems

(NYSE:VEEV)

Select Model

Outperform 77 (OpenAI - 4o)

Rating:77Outperform

Price Target:

$317.00

▲(13.59% Upside)

Veeva Systems' overall stock score is driven by its robust financial performance and positive earnings call, which highlight strong profitability and strategic advancements. However, the high P/E ratio suggests potential overvaluation, and mixed technical indicators indicate no clear trend, tempering the overall score.

Positive Factors

Strong Financial Health

Veeva's robust financial health, characterized by high profitability and strong cash flow, provides a stable foundation for sustained growth and strategic investments.

Resolution of IQVIA Lawsuit

Resolving the IQVIA lawsuit allows Veeva to integrate IQVIA data, enhancing product offerings and opening new collaboration opportunities, strengthening its market position.

AI Development

Advancements in AI development position Veeva to expand its market size and improve operational efficiency, driving long-term growth and competitive advantage.

Negative Factors

Challenges with Product Adoption

Resistance to new product adoption can hinder growth in certain segments, requiring strategic adjustments to overcome market reluctance and drive uptake.

Flat Growth in Commercial Cloud

Flat growth in commercial cloud subscriptions suggests potential saturation or competitive pressures, necessitating innovation to reignite growth in this segment.

Market Resistance

Market resistance to new products like Compass Prescriber indicates potential challenges in achieving anticipated growth, impacting revenue projections.

Veeva Systems (VEEV) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$45.01B

Dividend YieldN/A

Average Volume (3M)1.34M

Price to Earnings (P/E)56.3

Beta (1Y)1.01

Revenue Growth15.33%

EPS Growth30.51%

CountryUS

Employees7,291

SectorHealthcare

Sector Strength45

IndustryMedical - Healthcare Information Services

Share Statistics

EPS (TTM)1.99

Shares Outstanding163,908,020

10 Day Avg. Volume1,307,197

30 Day Avg. Volume1,341,933

Financial Highlights & Ratios

PEG Ratio1.52

Price to Book (P/B)6.47

Price to Sales (P/S)13.75

P/FCF Ratio35.31

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue13.93

Enterprise Value/Gross Profit18.42

Enterprise Value/Ebitda49.26

Forecast

1Y Price Target

$316.46

Price Target Upside13.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering23

Veeva Systems Business Overview & Revenue Model

Company DescriptionVeeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM MyInsights, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva OpenData, Veeva Link, Veeva Network, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Patients; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

How the Company Makes MoneyVeeva Systems generates revenue primarily through subscription-based services. The company offers its software solutions via a cloud model, allowing customers to pay for access on a recurring basis. Key revenue streams include subscriptions to its various applications, such as Veeva Vault, Veeva CRM, and Veeva Network, which cater to different aspects of life sciences operations, including clinical trials, regulatory submissions, and commercial sales. Veeva also provides professional services to assist clients in implementing and optimizing its software. Significant partnerships with major pharmaceutical companies and ongoing investments in product development further contribute to its earnings, as does the growing demand for cloud-based solutions in the life sciences sector.

Veeva Systems Key Performance Indicators (KPIs)

Any

Revenue by Segment

Revenue by Segment
Shows revenue distribution across various business segments, indicating which segments drive growth and how diversified Veeva Systems' income streams are.

Chart InsightsVeeva Systems' Subscription Services segment has shown consistent growth, bolstered by strong performance in Vault CRM and Crossix, which saw over 30% year-over-year growth. Despite macroeconomic uncertainties, Veeva's strategic focus on AI and expansion into horizontal CRM markets is driving optimism. The Professional Services segment, however, shows fluctuating growth, possibly impacted by macro pressures. The company's robust execution and achievement of a $3 billion revenue run rate goal underscore its resilience and strategic agility in navigating market challenges.

Data provided by:

Main Street Data

Veeva Systems Earnings Call Summary

Earnings Call Date:Aug 27, 2025

(Q2-2026)

% Change Since: |

Next Earnings Date:Dec 03, 2025

Earnings Call Sentiment Positive

The earnings call highlighted strong financial performance and significant strategic advancements, particularly with the resolution of the IQVIA lawsuit and progress in AI development. Although there are some challenges, such as resistance to certain products and flat sequential growth in one segment, these are outweighed by the positive developments and future potential.

Q2-2026 Updates

Positive Updates

Strong Quarterly Performance

Veeva Systems Inc. reported total revenue of $789 million for the second quarter, exceeding their guidance. Non-operating income was $353 million.

Resolution of IQVIA Lawsuit

The longstanding dispute with IQVIA has been resolved, removing historical barriers and potentially unlocking significant opportunities for collaboration and data integration.

AI Development and Future Potential

Veeva is making significant progress with Veeva AI, expected to transform the industry by increasing efficiency. Although not contributing materially in 2026 or 2027, it is expected to significantly increase Veeva's market size over time.

Broad-Based R&D Subscription Growth

R&D subscriptions and services saw substantial growth, driven by broad-based execution and a stable environment.

Positive Customer Reaction to IQVIA Collaboration

The resolution with IQVIA received overwhelmingly positive feedback from customers, indicating potential for improved collaboration and integration.

Top 20 Vault CRM Commitments

Veeva Systems Inc. secured commitments from nine top 20 pharmaceutical companies for Vault CRM, marking significant progress in customer adoption.

Crossix Growth

Continued strong performance in Crossix, driven by both measurement and audience business segments.

Negative Updates

Challenges with Compass Prescriber Adoption

Veeva Systems Inc. faced resistance in the market for their Compass Prescriber product, partly due to underestimated resistance to change.

Sequential Flat Growth in Commercial Cloud Subscriptions

Commercial Cloud subscriptions were flat quarter-over-quarter, despite strength in Crossix.

Company Guidance

During the Veeva Systems Inc. fiscal 2026 second quarter earnings call, the company reported a strong performance, delivering total revenue of $789 million and non-operating income of $353 million, both exceeding guidance. The call highlighted progress in their industry cloud vision and the transformative potential of Veeva AI. They discussed the resolution of a longstanding dispute with IQVIA, which now allows for the integration of IQVIA data into Veeva's commercial products, unlocking significant opportunities. The company also raised its annual billings guidance by $35 million, reflecting confidence in their financial outlook. Additionally, Veeva noted ongoing strength in their Crossix segment, driven by both audience and measurement businesses, contributing to robust growth within their commercial cloud. Overall, the call emphasized Veeva's strategic advancements and optimistic future outlook, particularly in the AI space.

Veeva Systems Financial Statement Overview

Summary

Veeva Systems presents a robust financial profile with strong profitability, a solid balance sheet, and impressive cash flow metrics. The company demonstrates consistent revenue growth and efficient operations, supported by low leverage and high equity. Overall, Veeva Systems is well-positioned for continued financial success in the healthcare information services industry.

Income Statement

Very Positive

Veeva Systems demonstrates strong profitability with a TTM gross profit margin of 75.59% and a net profit margin of 27.29%. Revenue growth is steady at 3.95% TTM, indicating consistent expansion. EBIT and EBITDA margins are robust at 29.27% and 29.94% respectively, reflecting efficient operations. Overall, the company shows solid financial health with a positive growth trajectory.

Balance Sheet

Very Positive

The balance sheet is strong with a low debt-to-equity ratio of 0.0129, indicating minimal leverage and financial risk. Return on equity is healthy at 13.40% TTM, showcasing effective use of equity capital. The equity ratio is solid, reflecting a stable financial structure. Veeva Systems maintains a strong balance sheet with low debt and high equity.

Cash Flow

Very Positive

Cash flow metrics are impressive with a free cash flow growth rate of 12.48% TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.08, and the free cash flow to net income ratio is 0.99, both suggesting efficient cash flow management. Veeva Systems exhibits strong cash flow performance, supporting its operational and financial stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.97B	2.75B	2.36B	2.16B	1.85B	1.47B
Gross Profit	2.24B	2.05B	1.69B	1.55B	1.35B	1.06B
EBITDA	839.23M	730.82M	461.96M	488.21M	532.94M	407.25M
Net Income	809.93M	714.14M	525.71M	487.71M	427.39M	380.00M
Balance Sheet
Total Assets	8.00B	7.34B	5.91B	4.80B	3.82B	3.05B
Cash, Cash Equivalents and Short-Term Investments	6.40B	5.15B	4.03B	3.10B	2.38B	1.66B
Total Debt	85.45M	75.78M	55.77M	60.98M	54.59M	63.12M
Total Liabilities	1.36B	1.51B	1.27B	1.09B	904.83M	779.75M
Stockholders Equity	6.64B	5.83B	4.64B	3.72B	2.91B	2.27B
Cash Flow
Free Cash Flow	1.33B	1.07B	885.14M	766.96M	750.25M	542.56M
Operating Cash Flow	1.35B	1.09B	911.34M	780.47M	764.46M	551.25M
Investing Cash Flow	-755.30M	-700.14M	-1.08B	-1.01B	-346.15M	-333.63M
Financing Cash Flow	169.84M	26.11M	-16.19M	-19.38M	-4.14M	33.82M

Veeva Systems Technical Analysis

Technical Analysis Sentiment

Positive

Last Price279.08

Price Trends

50DMA

280.78

Negative

100DMA

271.67

Positive

200DMA

249.10

Positive

Market Momentum

MACD

-1.23

Negative

RSI

50.91

Neutral

STOCH

49.51

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VEEV, the sentiment is Positive. The current price of 279.08 is above the 20-day moving average (MA) of 278.18, below the 50-day MA of 280.78, and above the 200-day MA of 249.10, indicating a neutral trend. The MACD of -1.23 indicates Negative momentum. The RSI at 50.91 is Neutral, neither overbought nor oversold. The STOCH value of 49.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VEEV.

Veeva Systems Risk Analysis

Veeva Systems disclosed 43 risk factors in its most recent earnings report. Veeva Systems reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Veeva Systems Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	80 Outperform	13.61B	63.18	22.93%	―	19.45%	46.46%
HQY	79 Outperform	7.95B	57.87	6.79%	―	15.45%	37.72%
VEEV	77 Outperform	$45.01B	56.33	13.70%	―	15.33%	30.51%
GEHC	77 Outperform	34.99B	15.69	23.07%	0.18%	2.30%	41.46%
BTSG	76 Outperform	4.85B	92.19	3.76%	―	20.60%	0.00%
TEM	59 Neutral	15.02B	-73.52	-64.52%	―	59.84%	76.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

VEEV

Veeva Systems

279.08

64.20

29.88%

HQY

Healthequity

95.59

16.06

20.19%

DOCS

Doximity

73.60

32.72

80.04%

GEHC

GE Healthcare Technologies Inc

74.00

-16.12

-17.89%

BTSG

BrightSpring Health Services, Inc.

27.25

12.52

85.00%

TEM

Tempus AI, Inc. Class A

87.07

32.64

59.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025